drugset / Trial / NCT03704467
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
Phase 1
Completed
3 enrolled
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany · collab
NaSingle-groupOpen-labelTreatment
Summary
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
Timeline
- Start
- 2019-03-04
- Primary completion
- 2019-11-06
- Completion
- 2019-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 800 mg | Intravenous |
| Subject | Berzosertib | Small molecule | 40 mg/m2 | Intravenous |
| Subject | Berzosertib | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Berzosertib | Small molecule | 90 mg/m2 | Intravenous |
| Subject | Carboplatin | Small molecule | — | — |